| First Author | AlQudah M | Year | 2020 |
| Journal | Matrix Biol | Volume | 91-92 |
| Pages | 92-108 | PubMed ID | 32422329 |
| Mgi Jnum | J:299644 | Mgi Id | MGI:6501296 |
| Doi | 10.1016/j.matbio.2020.04.005 | Citation | AlQudah M, et al. (2020) Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biol 91-92:92-108 |
| abstractText | Fibrosis is characterized by excessive deposition of extracellular matrix components such as collagen in tissues or organs. Fibrosis can develop in the heart, kidneys, liver, skin or any other body organ in response to injury or maladaptive reparative processes, reducing overall function and leading eventually to organ failure. A variety of cellular and molecular signaling mechanisms are involved in the pathogenesis of fibrosis. The renin-angiotensin-aldosterone system (RAAS) interacts with the potent Transforming Growth Factor beta (TGFbeta) pro-fibrotic pathway to mediate fibrosis in many cell and tissue types. RAAS consists of both classical and alternative pathways, which act to potentiate or antagonize fibrotic signaling mechanisms, respectively. This review provides an overview of recent literature describing the roles of RAAS in the pathogenesis of fibrosis, particularly in the liver, heart, kidney and skin, and with a focus on RAAS interactions with TGFbeta signaling. Targeting RAAS to combat fibrosis represents a promising therapeutic approach, particularly given the lack of strategies for treating fibrosis as its own entity, thus animal and clinical studies to examine the impact of natural and synthetic substances to alter RAAS signaling as a means to treat fibrosis are reviewed as well. |
